Skip to main navigation
  • Recent News
  • Investors
  • Contact Us
Avadel pharmaceutical logo
  • Home
  • Our Focus
  • Culture & Careers
  • Recent News
  • Investors
  • Contact Us

Breadcrumb

  1. Home
  2. Investors
  3. Press Releases
  4. Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Press Releases

Printer Friendly Version View printer-friendly version << Back
September 2, 2021 at 8:00 AM EDT

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

PDF Version

DUBLIN, Ireland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming virtual investor conferences in September:

  • 2021 Wells Fargo Virtual Healthcare Conference: Fireside chat on Friday, September 10, 2021 at 4:00 p.m. E.T.
  • Morgan Stanley 19th Annual Global Healthcare Conference: Fireside chat on Thursday, September 9, 2021 at 9:30 a.m. E.T.
  • H.C. Wainwright’s 23rd Annual Global Investment Conference: Fireside chat on Monday, September 13, 2021 at 7:00 a.m. E.T.
  • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: Fireside chat on Wednesday, September 22, 2021 at 10:45 a.m. E.T.

A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.

About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292


Primary Logo

Source: Avadel Pharmaceuticals plc

Tools

  • Print Page
  • RSS
  • E-mail Alerts

Investor Relations

  • Investors
  • News & Events
    • Press Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
  • Corporate Governance
    • Governance Highlights
    • Management Team
    • Board of Directors
    • Committee Composition
    • Annual General Meeting
  • Shareholder Services
    • Investor FAQs
    • Information Request
    • E-mail Alerts
    • IR Contacts
  • Our Focus
  • Culture & Careers
  • Investors
  • Recent News
  • Contact Us
  • Home
  • Our Focus
  • Culture & Careers
  • Contact Us
  • Recent News
  • Investors
  • Privacy Policy
  • Corporate Compliance
  • Terms and Conditions

The Avadel logo, the droplet brand mark, and other brands are trademarks of an Avadel company. © 2022 Avadel. All rights reserved.

PM-US-AVGEN-0115

We Care About Your Privacy

This website uses cookies. By using our website without changing your cookie settings, you agree to our use of cookies as described in our updated Privacy Policy.

You are about to leave the Avadel website.

Do you want to continue?

Avadel is not responsible for the content or availability of third party sites.